Related Experiment Video
Updated: Jul 18, 2026
08:32
Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker
Published on: December 18, 2014
Bisoprolol: a new beta-adrenoceptor blocking drug
1Department of Clinical Pharmacology, University College London, U.K.
European Heart Journal
|December 1, 1987
Summary
Bisoprolol, a highly beta 1-selective beta-blocker, effectively treats angina, arrhythmias, and hypertension with a favorable side-effect profile. Its once-daily dosing is supported by a 10-12 hour half-life.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Bisoprolol is a novel beta 1-selective beta-adrenoceptor antagonist.
- It lacks intrinsic sympathomimetic activity.
- Its selectivity is confirmed in studies involving asthmatic patients.
Purpose of the Study:
- To evaluate the hemodynamic effects of bisoprolol.
- To assess its efficacy in treating cardiovascular conditions like angina, arrhythmias, and hypertension.
- To compare its efficacy and pharmacokinetic profile with other cardiovascular drugs.
Main Methods:
- Hemodynamic monitoring at rest and during exercise.
- Clinical trials in patients with angina pectoris, arrhythmias, and hypertension.
- Pharmacokinetic studies assessing half-life, metabolism, and excretion.
- Comparative studies against atenolol, verapamil, nifedipine, and diuretics.
Main Results:
- Bisoprolol reduces heart rate and cardiac output, and increases peripheral resistance.
- It demonstrates significant efficacy in angina, arrhythmias, and hypertension, comparable to atenolol, verapamil, and nifedipine.
- Its pharmacokinetic profile supports once-daily administration with a half-life of 10-12 hours.
- Bisoprolol exhibits a favorable side-effect profile.
Conclusions:
- Bisoprolol is an effective beta 1-selective beta-blocker for cardiovascular conditions.
- Its pharmacokinetic properties allow for convenient once-daily dosing.
- The drug presents a favorable safety and efficacy profile compared to other agents.
Related Concept Videos
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:17Antihypertensive Drugs: Action of β1 Blockers
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
01:28Antihypertensive Drugs: Types of β-Blockers
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...